MANTIS Endoscopic Clipping Study
MANTIS Clip Study: A Prospective, Multi-Center, All-Comer MANTIS Endoscopic Clipping Study:
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
To document clinical effectiveness and safety when used per indication within the GI tract for the purpose of:
- Endoscopic marking
Hemostasis for:
- Mucosal/sub-mucosal defects < 3 cm
- Bleeding ulcers
- Arteries < 2 mm
- Polyps < 1.5 cm in diameter
- Diverticula in the colon
- Prophylactic clipping to reduce the risk of delayed bleeding post lesion resection
- Anchoring to affix jejunal feeding tubes to the wall of the small bowel
- As a supplementary method, closure of GI tract luminal perforations < 20 mm that can be treated conservatively
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Andrea Burbage
- Phone Number: 7812544679
- Email: andrea.burbage@bsci.com
Study Contact Backup
- Name: Huma Preston
- Phone Number: 5086834813
- Email: huma.preston@bsci.com
Study Locations
-
-
Onterio
-
Toronto, Onterio, Canada, M5B 1W8
- St Michael's Hospital
-
-
Quebec
-
Montréal, Quebec, Canada, H2X 0A9
- Centre hospitalier de l'Université de Montréal (CHUM)
-
-
-
-
Xuhui District
-
Shanghai, Xuhui District, China, 200031
- Shanghai Zhongshan Hospital
-
-
-
-
Shatin
-
Hong Kong, Shatin, Hong Kong
- Prince of Wales Hospital the Chinese University of Hong Kong
-
-
-
-
Telangana
-
Hyderabad, Telangana, India, 500082
- Asian Institute of Gastroenterology
-
-
-
-
Koto-Ku
-
Tokyo, Koto-Ku, Japan, 1358577
- Showa University Koto Toyosu Hospital
-
-
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth Hitchcock Medical Center
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject indicated for endoscopic clipping per local standard of practice.
- Willing and able to comply with the study procedures and provide written informed consent to participate in the study.
Exclusion Criteria:
- Subjects who are currently enrolled in another investigational study that would directly interfere with the current study, without prior written approval from the sponsor.
- Subjects who the investigator deems at risk for study device or procedure related complications per the Instructions for Use (IFU). where commercially available or the Investigator Brochure (IB) for countries where the study device is not approved.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Hemostasis of Active Bleeding
Time Frame: Index Procedure
|
Clinical success defined as hemostasis of an active bleeding assessed at the time of the index clipping procedure
|
Index Procedure
|
|
Number of Participants With Prophylactic Hemostasis
Time Frame: Up to 30 Days after the index clipping procedure
|
Clinical success defined as hemostasis as a prophylactic measure to minimize risk of a delayed bleeding post lesion resection, defined as absence of a bleeding SAE up to 30 days after the index clipping procedure
|
Up to 30 Days after the index clipping procedure
|
|
Number of Lesions With Defect Closures
Time Frame: Index Procedure
|
Clinical success defined as defect closure
|
Index Procedure
|
|
Number of Participants With Serious Adverse Events
Time Frame: Up to 30 Days after the Endocsopic clipping procedure
|
Rate of serious adverse events (SAEs) related to the MANTIS clip or the endoscopic study portion of the procedure
|
Up to 30 Days after the Endocsopic clipping procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clip deployment
Time Frame: Procedure
|
Incidents of success at placement defined as ability to deploy the endoscopic clips in satisfactory position
|
Procedure
|
|
Closure
Time Frame: Procedure
|
Incidents of ability to approximate defect edges for secured closure.
|
Procedure
|
|
Delayed bleeding
Time Frame: 30 Days
|
Incidents of post procedural bleeding, defined as a severe bleeding event that required hospitalization, a blood transfusion (>5 units), or another invasive intervention (angiographic or surgery)
|
30 Days
|
|
Active bleeding hemostasis
Time Frame: 7 Days
|
Rate of patients requiring additional modalities of hemostasis.
Report of hemostasis of active bleeding 7 days after the index study procedure, defined as ability to stop the active bleed at the time of the study procedure and/or with additional clipping procedures to provide hemostasis of continued or recurrent bleeding within 7 days of the index study procedure
|
7 Days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Daniel von Renteln, Md, Centre hospitalier de l'Université de Montréal (CHUM)
- Principal Investigator: Jeff Mosko, MD, Unity Health Toronto
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 92851066
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.